Trilogy Capital Inc. Abb Vie Inc. Transaction History
Trilogy Capital Inc.
- $1.87 Billion
- Q1 2025
A detailed history of Trilogy Capital Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 22,094 shares of ABBV stock, worth $4.33 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
22,094
Previous 15,824
39.62%
Holding current value
$4.33 Million
Previous $2.81 Million
64.67%
% of portfolio
0.25%
Previous 0.15%
Shares
30 transactions
Others Institutions Holding ABBV
# of Institutions
4,201Shares Held
1.29BCall Options Held
17.1MPut Options Held
15.1M-
Vanguard Group Inc Valley Forge, PA173MShares$33.9 Billion0.55% of portfolio
-
Black Rock Inc. New York, NY136MShares$26.8 Billion0.54% of portfolio
-
State Street Corp Boston, MA79.6MShares$15.6 Billion0.57% of portfolio
-
Jpmorgan Chase & CO New York, NY51.8MShares$10.1 Billion0.75% of portfolio
-
Morgan Stanley New York, NY39.7MShares$7.78 Billion0.51% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $347B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...